DLTs are defined as any of the following toxicities and judged by the Investigator and/or the Sponsor to be not attributable to the disease or disease-related processes under investigation: Grade 4 neutropenia for more than 7 days; Grade greater than or equal to (>=) 3 febrile neutropenia; Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with non-traumatic bleeding; Grade >= 3 nausea/vomiting and/or diarrhea that has not improved within 72 hours despite adequate and optimal treatment; Any other Grade >= 3 non-hematological AE, except alopecia or Grade 3 nauseas/vomiting and/or diarrhea that has improved within 72 hours with optimal treatment.

Safety run-in analysis set (SRIAS): all FAS/SAF participants treated during the safety run-in period who received at least 75% of the tepotinib and osimertinib planned dose and completed the DLT period (3 weeks after start of study treatment), or who experienced a DLT during the DLT period regardless of the received amount of each study treatment component.

Objective response was defined as percentage of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD) .CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic Epidermal Growth Factor Receptor mutation positive (EGFRm+) Non-Small Cell Lung Cancer (NSCLC) and Mesenchymal-Epithelial Transition factor (MET) amplification, determined centrally by FISH (central TBx FISH testing [T+]).

Objective response was defined as percentage of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD) .CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The secondary analysis set for efficacy included all modified Full Analysis Set (mFAS) participants with advanced or metastatic Epidermal Growth Factor Receptor mutation positive (EGFRm+) Non-Small Cell Lung Cancer (NSCLC) and Mesenchymal-Epithelial Transition factor (MET) amplification, determined centrally by liquid biopsy (LBx) test (L+).

Objective response was defined as percentage of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD) .CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]).

An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as events with onset date or worsening during the on-treatment period. TEAEs included both serious and non-serious TEAEs. Treatment-related TEAEs is defined as reasonably related to the study intervention.

Safety (SAF) analysis set included all participants who were administered any dose of any study treatment.

The laboratory measurements included hematology, biochemistry, coagulation and urinalysis. Number of participants with clinically significant abnormalities in laboratory values reported as treatment related TEAEs were reported. Clinical significance was decided by investigator.

Safety (SAF) analysis set included all participants who were administered any dose of any study treatment.

Vital signs included systolic blood pressure (SBP) and diastolic blood pressure (DBP), pulse rate (PR), respiratory rate (RR) body weight (BW) and body temperature (BT). Markedly abnormal value (MAV) criteria for vital signs: SBP and DBP: maximal on treatment (TR) increase or decrease greater than (>) 40 millimeter of mercury (mmHg); PR: maximal on TR increase or decrease >40 beats per minute (bpm); RR: maximal on TR increase or decrease >10 breaths per minute (breaths/minute), BW: maximum on TR increase or decrease >=10% and BT: maximal on TR increase greater than or equal to (>=)2 degree Celsius. Number of participants who met the MAV criteria for vital signs at least once post dose were reported.

Safety (SAF) analysis set included all participants who were administered any dose of any study treatment.

ECOG performance status measured to assess participant's performance status on a scale of 0 to 5, where 0 = Fully active, able to carry on all pre-disease activities without restriction; 1 = Restricted in physically strenuous activity, ambulatory and able to carry out light or sedentary work; 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities; 3 = Capable of only limited self-care, confined to bed/chair for more than 50 percent of waking hours; 4 = Completely disabled, cannot carry on any self-care, totally confined to bed/chair; 5 = dead. ECOG performance status was reported in terms of number of participants with shifts in score from baseline value vs worst post-baseline value (that is [i.e.] highest score).

Safety (SAF) analysis set included all participants who were administered any dose of any study treatment.

Electrocardiograms (ECG) was obtained after the participant has been in a semi-supine position for at least 5 min. ECG parameters included heart rate, PQ/PR duration, QRS and QT duration, QT Interval. Clinical significance was determined by the investigator. Number of participants with clinically significant abnormalities in 12-lead ECG were reported.

Safety (SAF) analysis set included all participants who were administered any dose of any study treatment.

Objective response was defined as percentage of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]).

Confirmed CR was defined as the disappearance of all evidence of target and non-target lesions.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]).

Confirmed CR was defined as the disappearance of all evidence of target and non-target lesions.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]).

DOR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response [CR] or Partial Response [PR]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]). Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.

DOR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response [CR] or Partial Response [PR]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]). Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.

Disease control rate is defined as the percentage of participants with objective resposne (complete resposne [CR] or partial resposne [PR] or stable disease [SD]). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD while on study. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]).

Disease control rate is defined as the percentage of participants with objective resposne (complete resposne [CR] or partial resposne [PR] or stable disease [SD]). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD while on study. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]).

PFS was defined as the time is defined as the time from first administration of study treatment to the date of the first documentation of PD or death due to any cause within 126 days of the last tumor assessment, whichever occurs first. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]).

PFS was defined as the time is defined as the time from first administration of study treatment to the date of the first documentation of PD or death due to any cause within 126 days of the last tumor assessment, whichever occurs first. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]).

Overall survival is defined as the time from first administration of study treatment to the date of death.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]).

Objective response was defined as percentage of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The secondary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by liquid biopsy (LBx) test (L+).

Confirmed CR was defined as the disappearance of all evidence of target and non-target lesions.

The secondary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by liquid biopsy (LBx) test (L+).

Confirmed CR was defined as the disappearance of all evidence of target and non-target lesions.

The secondary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by liquid biopsy (LBx) test (L+).

DOR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response [CR] or Partial Response [PR]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The secondary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by liquid biopsy (LBx) test (L+). Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.

DOR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response [CR] or Partial Response [PR]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The secondary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by liquid biopsy (LBx) test (L+). Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.

Disease control rate is defined as the percentage of participants with objective resposne (complete resposne [CR] or partial resposne [PR] or stable disease [SD]). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD while on study. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The secondary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by liquid biopsy (LBx) test (L+).

Disease control rate is defined as the percentage of participants with objective resposne (complete resposne [CR] or partial resposne [PR] or stable disease [SD]). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD while on study. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The secondary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by liquid biopsy (LBx) test (L+).

PFS was defined as the time is defined as the time from first administration of study treatment to the date of the first documentation of PD or death due to any cause within 126 days of the last tumor assessment, whichever occurs first. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The secondary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by liquid biopsy (LBx) test (L+).

PFS was defined as the time is defined as the time from first administration of study treatment to the date of the first documentation of PD or death due to any cause within 126 days of the last tumor assessment, whichever occurs first. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The secondary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by liquid biopsy (LBx) test (L+).

Overall survival is defined as the time from first administration of study treatment to the date of death.

The secondary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by liquid biopsy (LBx) test (L+).

Objective response was defined as percentage of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD) .CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]).

Confirmed CR was defined as the disappearance of all evidence of target and non-target lesions.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]).

Confirmed CR was defined as the disappearance of all evidence of target and non-target lesions.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]).

DOR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response [CR] or Partial Response [PR]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]). Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.

DOR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response [CR] or Partial Response [PR]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]). Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.

Disease control rate is defined as the percentage of participants with objective resposne (complete resposne [CR] or partial resposne [PR] or stable disease [SD]). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD while on study. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]).

Disease control rate is defined as the percentage of participants with objective resposne (complete resposne [CR] or partial resposne [PR] or stable disease [SD]). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD while on study. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]).

PFS was defined as the time is defined as the time from first administration of study treatment to the date of the first documentation of PD or death due to any cause within 126 days of the last tumor assessment, whichever occurs first. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]).

PFS was defined as the time is defined as the time from first administration of study treatment to the date of the first documentation of PD or death due to any cause within 126 days of the last tumor assessment, whichever occurs first. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]).

The EQ-5D-5L questionnaire is a generic measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D-5L profile defines health in terms of mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Each dimension has five levels: 1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, and 5: extreme problems. The responses were used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 was the worst health you can imagine and 100 was the best health you can imagine.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]). Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure.

EORTC QLQ-C30 was a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). The EORTC QLQ-C30 GHS/QoL score ranged from 0 to 100; High score indicated better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]). Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure.

NSCLC-SAQ was a question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 5 domains: cough, pain, dyspnea, fatigue, and appetite. The NSCLC-SAQ score ranged from 0 to 20; High score indicated more severe NSCLC-related symptomatology. mains: cough, pain, dyspnea, fatigue, and appetite.

The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing [T+]). Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure.

Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was calculated according to the mixed log-linear trapezoidal rule.

Pharmacokinetic analysis set included all FAS/SAF participants who have no important events affecting PK and provide at least one measurable post-dose concentration. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure and "number analyzed" signifies those participants who were evaluable at specified timepoints for this outcome measure.

Cmax was obtained directly from the concentration versus time curve.

PK analysis set included all FAS/SAF participants who have no important events affecting PK and provide at least one measurable post-dose concentration. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure and "number analyzed" signifies those participants who were evaluable at specified timepoints for this outcome measure.

Tmax was obtained directly from the concentration versus time curve.

PK analysis set included all FAS/SAF participants who have no important events affecting PK and provide at least one measurable post-dose concentration. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure and "number analyzed" signifies those participants who were evaluable at specified timepoints for this outcome measure.

CL/f was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. CL/f was calculated as Dose/AUC0-inf, where AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. AUC0-inf was calculated as AUC0-t + Clast pred/Lambda Z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the lower limit of quantification (LLQ) and Lambda Z was the apparent terminal rate constant determined from the terminal slope of the log-transformed plasma concentration curve.

As per changes in planned analysis, the PK parameter (CL/f) was not assessed.

Vz/f: the distribution of a study drug between plasma and the rest of the body after oral dosing. For single dose Vz/f = Dose/(AUC0-inf*Lambda Z), where AUC0-inf = (AUC0-t + Clast pred/Lambda Z). Clastpred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the LLQ and Lambda Z = the apparent terminal rate constant determined from the terminal slope of the log-transformed plasma concentration curve.

As per changes in planned analysis, the PK parameter (Vz/f) was not assessed.

Percentage of participants with resistant mutations of the EGFR gene or other pathways as assessed in ctDNA were reported.

As per changes in planned analysis, the data for mutation status in EGFR and other pathways in ctDNA at baseline and progression were not collected with the assay used to screen for MET amplification in ctDNA.